First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib

Clinical Nuclear Medicine

Volumn 37, Issue 6, 2012, Pages 539-544

  Putzer, Daniel ^a   Gabriel, Micheal ^a   Kroiss, Alexander ^a   Madleitner, Ruth ^a   Eisterer, Wolfgang ^a   Kendler, Dorota ^a   Uprimny, Christian ^a   Bale, Reto J ^a   Gastl, Günther ^a   Virgolini, Irene J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

bor tezomib; dedifferentiated thyroid cancer; prog ressive thyroid cancer; proteasome inhibitor therapy; radioiodine non avidity

Indexed keywords

BORTEZOMIB; FLUORODEOXYGLUCOSE F 18; IODIXANOL; RADIOPHARMACEUTICAL AGENT; THYROGLOBULIN; TROPISETRON;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE METASTASIS; CANCER THERAPY; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; PILOT STUDY; POLYNEUROPATHY; POSITRON EMISSION TOMOGRAPHY; RADIOIODINE NONAVID THYROID CANCER; SOFT TISSUE METASTASIS; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BORONIC ACIDS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; QUALITY OF LIFE; THYROID NEOPLASMS; TREATMENT FAILURE;

EID: 84861450011     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824c5f24     Document Type: Article

References (39)

1. Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother. 2008;62:559-563.
2. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996;172:692-694. (Pubitemid 27024782)
3. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91:2892-2899. (Pubitemid 44271732)
4. Fagin JA, Tuttle RM, Pfister DG. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2621-2624.
5. Sherman SI. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008;20:648-661.
6. Haugen BR. Management of the patient with progressive radioiodine nonresponsive disease. Sem Surg Oncol. 1999;16:34-41.
7. Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008;26:4701-4704.
8. Antonelli A, Ferri C, Ferrari SM, et al. New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol. 2010;2010:921682.
9. Braga-Basaria M, Ringel MD. Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab. 2003;88:1947-1960. (Pubitemid 36549861)
10. Deshpande HA, Gettinger SN, Sosa JA. Targeted therapy for thyroid cancer: An updated review of investigational agents. Curr Opin Investig Drugs. 2010;11: 661-668.
11. Gabriel M, Andergassen U, Putzer D, et al. Individualized peptide-relatedradionuclide- therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54: 92-99.
12. Iten F, Muller B, Schindler C, et al. E(90)Yttrium-DOTA-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial. Cancer. 2009;115:2052-2062.
13. Margulies DJ, Blum M. Somatostatin receptor scintigraphy as a potential diagnostic and treatment modality for thyroid follicular-cell-derived cancers. Thyroid. 2010;20:671-672.
14. Bertagna F, Giubbini R, Savelli G, et al. A patient with medullary thyroid carcinoma and right ventricular cardiac metastasis treated by (90)Y-Dotatoc. Hell J Nucl Med. 2009;12:161-164.
15. Iten F, Mu ller B, Schindler C, et al. Response to E90Yttrium-DOTA-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res. 2007;13: 6696-6702. (Pubitemid 350206806)
16. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26:4714-4719.
17. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27:1675-1684.
18. Cabanillas ME, Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience. J Clin Endocrinol Metab. 2010;95:2588-2595.
19. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161:923-931.
20. Nagaiah G, Fu P, Wasman JK, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. J Clin Oncol. 2009;27: 15sEabstr 6058
21. Brose MS, Troxel AB, Redlinger M, et al. Effect of BRAFV660E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol. 2009;27:6002.
22. Sherman SI. Targeted therapy of thyroid cancer. Biochem Pharm. 2010;80: 592-601.
23. Sherman SI, Tuttle RM, Ball DW, et al. NCCN practice guidelines in oncology:thyroid carcinoma. J Natl Compr Canc Netw. 2009;1.
24. Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008;359:31-42. (Pubitemid 351931094)
25. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009;27:3794-3801.
26. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26:4708-4713.
27. Wells Jr SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28:767-772.
28. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2664-2671.
29. Bible KC, Smallridge RC, Maples WJ, et al. Phase II trial of pazopanib in progressive, metastatic iodine-sensitive differentiated thyroid cancers. J Clin Oncol. 2009;27:3521.
30. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2007;18:317-323.
31. Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid. 2007;17:663-670. (Pubitemid 47311556)
32. Ain KB, Lee C, Holbrook KM, et al. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine unresponsive thyroid carcinomas: preliminary results. J Clin Oncol. 2008;26:6027.
33. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celexocib in metastatic differentitated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91: 2201-2204. (Pubitemid 43855005)
34. Argiris A, Agarwala SS, Karamouzis MV, et al. A phase II trial of docorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs. 2007;26:183-188.
35. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers revelas distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009; 69:4885-4893.
36. Mitsiades CS, McMillin D, Kotoula V, et al. Antitumor effects of the proteasome inhibitor Bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006;91:4013-4021. (Pubitemid 44536879)
37. Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov. 2003;8:611-612.
38. Decristoforo C, Knopp R, von Guggenberg E, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun. 2007;28: 870-875. (Pubitemid 47494113)
39. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(suppl 1):122-150.